REGENXBIO

Rockville, Md. – October 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will host a three-hour investor event on October 20, 2026 to review its wet age-related macular degeneration (wet AMD) gene therapy program, with topline pivotal data anticipated in the fourth quarter of 2026.

Event runs 1:00 p.m. to 4:00 p.m. ET in New York and online

The session will be held in person in New York and streamed by webcast. It will cover the clinical program for surabgene lomparvovec (sura-vec, ABBV-RGX-314), which REGENXBIO is developing in collaboration with AbbVie.

Management and five retina specialists to address commercial readiness

REGENXBIO management and retina specialists will discuss the treatment landscape, unmet need, the ATMOSPHERE and ASCENT pivotal trials, and the commercial readiness of sura-vec in wet AMD.

Five key opinion leaders are scheduled to appear:

Rockville, Md. – September 24, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) reported that 60% of Dose Level 3 participants with three-year follow-up data in its Phase II ALTITUDE study achieved a greater-than-2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) after a single in-office treatment with investigational gene therapy sura-vec, with no vision-threatening events recorded among responders.

Three-year data confirm durable DRSS improvement without repeat injections

In long-term follow-up as of August 17, 2026, six of ten Dose Level 3 participants with non-proliferative diabetic retinopathy (NPDR) who reached the three-year visit sustained a greater-than-2-step DRSS improvement without additional diabetic retinopathy treatment. The suprachoroidal delivery used Dose Level 3 (1.0x10^12 GC/eye) combined with short-course prophylactic topical steroids.

Rockville, Maryland – September 11, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will hold fireside chats at two major investor healthcare conferences in New York this month.

REGENXBIO confirms back-to-back fireside chats on September 15 and 16

The gene therapy company will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Both sessions will take place in New York, NY.